Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05356221 · ClinicalTrials.gov registry record
Cross-sectional Evaluation of the Subjective Performance and Satisfaction With Ponto Sound Processors
A clinical trial, sponsored by Oticon Medical.
- Completed
- Registry status
- 170
- Enrollment target
NCT05356221: Completed study, sponsored by Oticon Medical.
NCT05356221 is a clinical trial that has completed, run by Oticon Medical. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05356221 has completed, sponsored by Oticon Medical.
- COMPLETED
- Registry status
- 170 participants
- Enrollment target
Study Summary
The study is a non-interventional, observational, cross-sectional, study on users of Ponto sound processors. The purpose of this study is to evaluate subjectively assessed hearing performance and satisfaction with Oticon Medical's sound processors fitted with the Genie Medical fitting software.
Primary Outcome
International Outcome Inventory for Hearing Aids score. 5 item categorical scale ranging from worst outcome (1) to best outcome (5). Evaluate subjectively assessed overall hearing performance and satisfaction with the Oticon Medical's Ponto sound processors.
Interventions
- DEVICE Ponto Sound processor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2024-09-01 |
What the finished NCT05356221 record still lists
NCT05356221 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ponto Sound processor is the first listed.
NCT05356221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05356221 about?
NCT05356221 is a clinical study titled "Cross-sectional Evaluation of the Subjective Performance and Satisfaction With Ponto Sound Processors". The study is a non-interventional, observational, cross-sectional, study on users of Ponto sound processors. The purpose of this study is to evaluate subjectively assessed hearing performance and satisfaction with Oticon Medical's sound processors fitted with the Genie Medical fitting software.
What is the current status of trial NCT05356221?
This trial is currently completed. The enrollment target is 170 participants. The study started on 2022-04-11. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT05356221?
The interventions under investigation include: Ponto Sound processor (DEVICE).
Who is sponsoring clinical trial NCT05356221?
This trial is sponsored by Oticon Medical, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI